23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
The fight against COVID19 | -0.27% | - | - | - |
^GSPC | +0.80% | +2.92% | +23.48% | +5574.74% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 146.67 | +1.39 | +0.96% | 4:00 pm GMT-4 | 14.62M | 7.70M | 352.99B |
ABBV | AbbVie Inc. | 161.24 | +4.93 | +3.15% | 4:05 pm GMT-4 | 15.66M | 5.78M | 284.73B |
PFE | Pfizer Inc. | 28.66 | +0.46 | +1.63% | 4:00 pm GMT-4 | 78.29M | 42.12M | 162.40B |
SNY | Sanofi | 49.03 | +1.20 | +2.51% | 4:00 pm GMT-4 | 2.10M | 1.98M | 122.55B |
REGN | Regeneron Pharmaceuticals, Inc. | 980.16 | +10.25 | +1.06% | 4:00 pm GMT-4 | 833.17k | 440.60k | 108.00B |
GSK | GSK plc | 44.77 | +0.75 | +1.70% | 4:00 pm GMT-4 | 3.62M | 3.12M | 91.29B |
GILD | Gilead Sciences, Inc. | 64.26 | +0.18 | +0.28% | 4:00 pm GMT-4 | 14.51M | 7.04M | 80.06B |
MRNA | Moderna, Inc. | 142.57 | -8.92 | -5.89% | 4:00 pm GMT-4 | 7.18M | 4.06M | 54.64B |
TAK | Takeda Pharmaceutical Company Limited | 13.35 | +0.32 | +2.46% | 4:00 pm GMT-4 | 1.85M | 1.57M | 41.89B |
BNTX | BioNTech SE | 100.6 | +1.85 | +1.87% | 4:00 pm GMT-4 | 1.62M | 723.66k | 24.24B |
NVAX | Novavax, Inc. | 15.04 | -0.21 | -1.38% | 4:00 pm GMT-4 | 15.74M | 12.48M | 2.22B |
VIR | Vir Biotechnology, Inc. | 10.27 | -0.12 | -1.15% | 4:00 pm GMT-4 | 971.03k | 889.63k | 1.40B |
INO | Inovio Pharmaceuticals, Inc. | 10.13 | +0.36 | +3.68% | 4:00 pm GMT-4 | 254.67k | 427.41k | 262.48M |
Shockwave specialises in CAD and PAD treatments.
The trial has shown superior PFS and improved tolerability for patients with newly diagnosed Hodgkin lymphoma.
OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2024--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall dis